Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction Therapy in Patients With Untreated Multiple Myeloma (MM), Stratified for Markers of Bortezomib Resistance

NCT00872521 is registered in ClinicalTrials.gov with Janssen-Cilag Pty Ltd as lead sponsor.

NCT NCT00872521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00872521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction Therapy in Patients With Untreated Multiple Myeloma (MM), Stratified for Markers of Bortezomib Resistance
Lead sponsor
Janssen-Cilag Pty Ltd
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2009
Completion date
November 30, 2011
Enrollment
107 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma